Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-UK vaccine roll-out to be slower than hoped, deliveries to pick up from May

Thu, 18th Mar 2021 07:17

* UK says global lumpy supply chain causing issues

* UK vaccine roll-out will be slower than hoped

* UK says vaccine deliveries to rise from May

* UK scolds EU over vaccine ban threat
(Adds detail, reaction from companies)

By Guy Faulconbridge and Kate Holton

LONDON, March 18 (Reuters) - Britain said on Thursday that
global supply bumps meant its vaccine roll-out would be slower
than hoped in coming weeks but it expected deliveries to
increase again in May, June and July.

British health officials warned on Wednesday that the
world's fastest big economy roll-out of the vaccine would face a
significant reduction in supplies from March 29.

Pfizer Inc and AstraZeneca Plc said their
delivery schedules had not been impacted, and Housing Secretary
Robert Jenrick refused to be drawn on whether the issue was due
to a problem with supply from India.

"We have less supply than we might have hoped for the coming
weeks but we expect it to increase again later," Jenrick told
the BBC.

"The vaccine roll-out will be slightly slower than we might
have hoped but not slower than the target," he said. "We have
every reason to believe that supply will increase in the months
of May, June and July."

Britain is on track to have given a first shot to half of
all adults in the next few days, making it one of the fastest
countries to roll out a vaccine.

So far 25.27 million people in the United Kingdom have had a
vaccine, around 48% of adults, and Jenrick said Britain remained
on track to have vaccinated priority groups by April 15 and all
adults by the end of July.

"We always said right from the beginning that a new
manufacturing process would have its lumps and bumps and that
has been the case in the past and I'm sure it will be in the
future," Jenrick told Sky.

"We're sourcing vaccines from all over the world and we are
experiencing occasionally some issues and that's led to this,
this issue with some supply in the coming weeks," he said.

Asked if the issue was supply from India, he declined to
discuss specific contracts.

SUPPLY BUMP

Britain is rolling out vaccines made by Pfizer and
AstraZeneca, with 10 million doses of the 100 million ordered
from AstraZeneca coming from the Serum Institute in India.

AstraZeneca said its domestic supply chain, which produces
most of its supply for Britain, was unaffected.

"Our UK domestic supply chain is not experiencing any
disruption and there is no impact on our delivery schedule,"
said a spokesman for the firm, which makes the vaccine developed
by the University of Oxford.

The announcement of a supply shortfall coincided with a
resurgence in tensions with the European Union, which is
frustrated by a lack of exports of AstraZeneca's vaccine from
Britain.

The EU threatened on Wednesday to ban exports of COVID-19
vaccines to Britain to safeguard scarce doses for its own
citizens, and Jenrick said the threat from European Commission
head Ursula von der Leyen was disappointing.

Pfizer, which supplies Britain with shots from Europe, said
first quarter deliveries to the UK remained on track and overall
supply for the second quarter remained unchanged. Jenrick said
he hoped no barriers to the importation of vaccines would be
erected by the bloc.

"I was surprised and disappointed by those comments but the
prime minister had spoken earlier in the year to Ursula von der
Leyen and she gave a very clear commitment, which was that the
EU would not engage in this sort of activity, that contractual
responsibilities would be honoured," Jenrick said.

"And that's exactly what we intend to do and I hope and
expect the EU to stick to their side of the bargain."
(Reporting by Guy Faulconbridge, Kate Holton and Alistair
Smout; editing by Sarah Young and Giles Elgood)

More News
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.